ENTERA BIO LTD. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ENTERA BIO LTD. (ENTX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-27
- ENTERA BIO LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.09M, a 48.93% increase from fiscal 2024.
- ENTERA BIO LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $1.40M, a 23.22% decline from fiscal 2023.
- ENTERA BIO LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $1.83M, a 30.31% decline from fiscal 2022.
- ENTERA BIO LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $2.62M, a 0.58% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $2.09M 10-K · filed 2026-03-27 |
| 2024-12-31 | $1.40M 10-K · filed 2026-03-27 |
| 2023-12-31 | $1.83M 10-K · filed 2025-03-28 |
| 2022-12-31 | $2.62M 10-K · filed 2024-03-08 |
| 2021-12-31 | $2.60M 10-K · filed 2023-03-31 |
| 2020-12-31 | $2.70M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |